Expertise in
64
conditions

Dr. Donald E. Goodin

Hematology | Oncology
Hardin Memorial Health Cancer Studies
521 Robinbrooke Blvd, 
Elizabethtown, KY 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
64
conditions
Hardin Memorial Health Cancer Studies
521 Robinbrooke Blvd, 
Elizabethtown, KY 

Overview

Donald Goodin is a Hematologist and an Oncologist practicing medicine in Elizabethtown, Kentucky.

Dr. Goodin is highly rated in 64 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Lung Cancer.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 10 clinical trials. Dr. Goodin is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in KY

Hospital Affiliations

Owensboro Health Twin Lakes Medical Center
UOFL HEALTH - JEWISH HOSPITAL And Mary & Elizabeth Hospital
Baptist Health Hardin
Baptist Health Louisville

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Hardin Memorial Health Cancer Studies
521 Robinbrooke Blvd, Elizabethtown, KY 42701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: May 18, 2026
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: July 17, 2025
Intervention Type: Other, Drug
Study Drug: Naloxegol
Study Phase: Phase 2
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
View 9 Less Clinical Trials

1 Total Publications

Molecular Tumor Board Review and Improved Overall Survival in Non-Small-Cell Lung Cancer.
Molecular Tumor Board Review and Improved Overall Survival in Non-Small-Cell Lung Cancer.
Journal: JCO precision oncology
Published: May 14, 2021
Similar Doctors
Expertise in
59
conditions
Dr. Michael D. Kommor
Hematology | Oncology
Expertise in
59
conditions
Dr. Michael D. Kommor
Hematology | Oncology
Referral may be required

Baptist Health Lagrange Kresge Pharmacy

4003 Kresge Way Ste 500, 
Louisville, KY 
 (39.9 miles away)
502-897-1166
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Kommor is a Hematologist and an Oncologist practicing medicine in Louisville, Kentucky. Dr. Kommor is highly rated in 59 conditions, according to our data. His clinical expertise encompasses Splenic Neoplasm, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Lung Cancer. Dr. Kommor is currently accepting new patients.

Expertise in
45
conditions
Dr. Udaya G. Joseph
Hematology | Oncology
Expertise in
45
conditions
Dr. Udaya G. Joseph
Hematology | Oncology
Referral may be required

Baptist Health Lagrange Kresge Pharmacy

4003 Kresge Way Ste 500, 
Louisville, KY 
 (39.9 miles away)
502-897-1166
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Udaya Joseph is a Hematologist and an Oncologist practicing medicine in Louisville, Kentucky. Dr. Joseph is highly rated in 45 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Myelodysplastic Syndrome (MDS), and Inflammatory Breast Cancer. Dr. Joseph is currently accepting new patients.

Expertise in
22
conditions
Dr. Ashok B. Raj
Hematology | Oncology
Expertise in
22
conditions
Dr. Ashok B. Raj
Hematology | Oncology
Referral may be required

Norton Children's Sleep Medicine-Novak Center

411 E Chestnut St, 
Louisville, KY 
 (37.3 miles away)
502-588-3600
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Ashok Raj is a Hematologist and an Oncologist practicing medicine in Louisville, Kentucky. Dr. Raj is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobin SC Disease, Immune Thrombocytopenic Purpura (ITP), Bone Marrow Aspiration, and Lithotripsy. Dr. Raj is currently accepting new patients.

Frequently Asked Questions about Dr. Donald E. Goodin

How do I make an appointment with Dr. Donald E. Goodin?

You can book an appointment with Dr. Donald E. Goodin by calling their office at 270-706-1535. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Donald E. Goodin a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Donald E. Goodin is classified as an Distinguished expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Donald E. Goodin specialize in?

While Dr. Donald E. Goodin is a Hematology, they have specific expertise in Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Donald E. Goodin participate in research or clinical trials?

Yes. Dr. Donald E. Goodin has published 1 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Dr. Donald E. Goodin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Donald E. Goodin accept my insurance?

Dr. Donald E. Goodin accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 270-706-1535 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goodin's expertise for a condition
ConditionClose
    View All 20 Distinguished Conditions
    View All 44 Advanced Conditions
    View All 126 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile